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Background: Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical beneﬁt when
combined with platinum-based chemotherapy in ﬁrst-line advanced non-small-cell lung cancer. We report the ﬁnal
overall survival (OS) analysis from the phase III AVAiL trial.
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m
2 and gemcitabine 1250 mg/m
2 for up to six
cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks
until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
Results: Signiﬁcant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-
up {hazard ratio (HR) [95% conﬁdence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456}
for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS
was not signiﬁcantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23),
P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple
lines of poststudy treatment. Updated safety results are consistent with those previously reported.
Conclusions: Final analysis of AVAiL conﬁrms the efﬁcacy of bevacizumab when combined with cisplatin–
gemcitabine. The PFS beneﬁt did not translate into a signiﬁcant OS beneﬁt, possibly due to high use of efﬁcacious
second-line therapies.
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introduction
Advanced non-small-cell lung cancer (NSCLC) is the leading
cause of cancer-related death. Although there is currently no
universally accepted standard regimen for the ﬁrst-line treatment
of advanced NSCLC, cisplatin–gemcitabine (CG) is widely used
in Europe on the basis of its favourable efﬁcacy and tolerability
proﬁle [1, 2]. Bevacizumab is an anti-vascular endothelial growth
factor mAb developed from the murine antibody A4.6.1 [3, 4].
The clinical beneﬁt of bevacizumab is well established across
a range of tumour types, including colorectal cancer [5, 6],
metastatic breast [7] and renal cancers [8]. In nonsquamous
NSCLC, the proven efﬁcacy and well-established safety proﬁle of
bevacizumab as a ﬁrst-line treatment have been demonstrated in
two randomised phase III trials [9, 10].
The Eastern Cooperative Oncology Group (ECOG) phase III
trial E4599 reported signiﬁcantly improved overall survival (OS;
study primary end point) with bevacizumab plus carboplatin–
paclitaxelversuscarboplatin–paclitaxelalone[hazardratio(HR)
0.79; median 12.3 versus 10.3 months; P = 0.003] [9].
Bevacizumab plus carboplatin–paclitaxel also signiﬁcantly
improved progression-free survival (PFS) and response rates
versus carboplatin–paclitaxel alone and had an acceptable safety
proﬁle. Theresultsof E4599showedthatbevacizumabistheﬁrst
agent to increase OS beyond the historical 1-year benchmark.
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III trial, evaluated bevacizumab (7.5 and 15 mg/kg every
3 weeks) in combination with CG. In AVAiL, the primary end
point of PFS was met, further proving the efﬁcacy of
bevacizumab in NSCLC. The results of the PFS analysis, other
secondary efﬁcacy end points and the safety analysis have
already been published [10]. Here, we report results of the OS
analysis from AVAiL, on the basis of a follow-up period of up
to 32 months (median ‡12.5 months). Some of these results
have been presented in abstract form [11].
patients and methods
patients
Eligible patients had histologically or cytologically documented, advanced
(stage IIIb with supraclavicular lymph node metastasis, malignant pleural
or pericardial effusion or stage IV) or recurrent nonsquamous NSCLC.
Patients with mixed non-small-cell tumour and small-cell tumour or mixed
adenosquamous carcinomas with a predominant squamous component
were excluded. Full details of patient inclusion and exclusion criteria have
been published previously [10]. Patients were recruited from February 2005
to August 2006 by 150 centres in 20 countries. The protocol was approved
by local independent ethics committees.
study design and treatments
Eligible patients were randomised to receive bevacizumab 7.5 mg/kg plus
CG, bevacizumab 15 mg/kg plus CG or high- or low-dose placebo plus CG.
Cisplatin was administered i.v. at 80 mg/m
2 on day 1 and gemcitabine was
administered i.v. at 1250 mg/m
2 on days 1 and 8. Chemotherapy was
repeated every 3 weeks for up to six cycles unless there was evidence of
disease progression or unacceptable toxicity. Blinded placebo or
bevacizumab was administered i.v. and given concurrently with
chemotherapy every 3 weeks on day 1. Further information on
randomisation, stratiﬁcation and strategies to maintain blinding is detailed
elsewhere [10]. Crossover from placebo to the bevacizumab groups was not
permitted. Bevacizumab and placebo were supplied by F. Hoffmann-La
Roche Ltd (Basel, Switzerland).
statistical analysis
The primary analysis population was the intent-to-treat (ITT) population,
which included all randomised patients. The per protocol (PP) population
included all patients with no major protocol violations who received at least
four cycles of study treatment and had at least one tumour assessment
during treatment or who terminated treatment before four cycles because of
disease progression or death. The PP analysis was a protocol-speciﬁed
efﬁcacy analysis.
The study was originally initiated with a two-stage adaptive design and
a primary end point of OS (deﬁned as the time from randomisation to
death from any cause). One of the bevacizumab groups was to be stopped
on the basis of an interim analysis of efﬁcacy (PFS) and safety at the end of
the ﬁrst stage, resulting in a two-arm study. Following the positive OS
results from E4599 [9], the study protocol was amended to facilitate trial
completion and interpretation, to accelerate reporting of the efﬁcacy data
and thus expedite the availability of a potentially active treatment option
for patients and to minimise the risk of the OS end point being confounded
by the increasing use of second-line therapies. The primary end point was
changed to PFS, and it was decided that both bevacizumab doses would be
explored. The study was not powered to detect an OS beneﬁt retaining the
two doses of bevacizumab but was fully powered for the primary end point
of PFS. No analysis comparing the pooled bevacizumab groups versus
placebo was carried out, as the criteria required to pool these data were not
met. Exploratory OS analyses for patients who did not receive postprotocol
therapies were carried out for the two bevacizumab arms (pooled data from
both groups) versus the placebo arm. Pre-planned exploratory subgroup
analyses of OS data were carried out on the basis of a variety of important
baseline factors: ECOG performance status, stage, gender and age (and also
albumin, lactate dehydrogenase and alkaline phosphatase but results are not
presented for these factors). Event-time distributions were estimated by
the Kaplan–Meier method. All analyses reported here were carried out from
a data cut-off on 30 November 2007.
results
Randomised patients (n = 1043) were assigned to bevacizumab
7.5 mg/kg plus CG (n = 345), bevacizumab 15 mg/kg plus CG
(n = 351) or placebo plus CG (n = 347). Of these, 57 patients
did not receive study therapy because of eligibility violations
(n = 27), withdrawal of consent (n = 16), adverse events
(n = 8) and other reasons (n = 6). Demographic and baseline
characteristics of all randomised patients, which have been
previously reported [10], were well balanced across treatment
groups.
treatment duration
The median number of cycles of chemotherapy and
bevacizumab–placebo was ﬁve for the placebo and 15 mg/kg
bevacizumab groups and six for the 7.5 mg/kg bevacizumab
group [10]. Most patients (94%) who were eligible to receive
single-agent bevacizumab maintenance therapy at cycle 7 did
so.
progression-free survival
The trial met its primary end point at the time of the ﬁrst
analysis, showing that PFS was signiﬁcantly prolonged with
bevacizumab compared with placebo (clinical cut-off 7 October
2006) [10].
The observed PFS beneﬁt was maintained with longer follow-
up (median 12.5–12.9 months across groups). At the time of
the OS analysis, PFS was signiﬁcantly longer in both
bevacizumab groups compared with placebo. Compared with
the placebo group, the risk of progression or death at any time
was reduced by 25% in the bevacizumab 7.5 mg/kg group [HR
0.75, 95% conﬁdence interval (CI): 0.64–0.87; P = 0.0003] and
by 15% in the bevacizumab 15 mg/kg group (HR 0.85, 95% CI
0.73–1.00; P = 0.0456).
response rate
At the time of the follow-up analysis, objective response rates
were 37.8% (P < 0.0001) and 34.6% (P = 0.0002) for
bevacizumab 7.5 mg/kg and 15 mg/kg, respectively, compared
with 21.6% for placebo.
overall survival
The total number of reported deaths was 715. Despite the trend
seen in OS at the time of the initial analysis favouring the
bevacizumab 7.5 mg/kg arm and the conﬁrmed reduction in
the risk of progression or death seen with longer follow-up,
ﬁnal analysis shows that the PFS beneﬁt did not translate into
a signiﬁcant OS beneﬁt. In the ITT population, the median OS
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increasing from 13.1 months for the placebo group to 13.6 and
13.4 months in the bevacizumab 7.5 mg/kg and bevacizumab
15 mg/kg groups, respectively (HR 0.93, 95% CI 0.78–1.11;
P = 0.420; HR 1.03, 95% CI 0.86–1.23; P = 0.761, respectively)
(Figure 1A). The results were similar in the PP population.
A large proportion of patients in AVAiL (61%–65%) received
poststudy therapy in each of the treatment arms (Table 1). In
order to estimate the impact of postprotocol therapies on the
results of the OS analysis, a hypothesis-generating exploratory
analysis examining the duration of OS in patients who did
not receive poststudy therapy was conducted (Figure 1B).
Without the potential inﬂuence of poststudy therapies, the
median OS (95% CI) was 8.7 (7.8–9.9) months for the pooled
bevacizumab groups versus 7.3 (5.9–8.9) months for the
placebo group (HR 0.84; P = 0.20). A clear separation of the
Kaplan–Meier curves for OS was observed between the
bevacizumab and the placebo groups; however, owing to the
Figure 1. Plots of Kaplan–Meier estimates for OS (ITT population) for the bevacizumab 7.5 mg/kg group and the bevacizumab 15 mg/kg group relative to
placebo, together with time to event data for the OS analysis in the ITT and PP populations (A) and for the subgroup of patients who did not receive
poststudy therapy (B). In panel b, data from the two bevacizumab groups have been pooled. CG, cisplatin–gemcitabine; CI, conﬁdence interval; HR, hazard
ratio; ITT, intent-to-treat; OS, overall survival; PP, per protocol.
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signiﬁcance. A similar analysis conducted for patients who
did receive poststudy therapy showed no difference between
treatment groups.
The analysis of OS for subgroups in AVAiL produced results
that were largely consistent with those for the overall ITT
population, except for the small subgroup of Asian patients for
whom a signiﬁcant beneﬁt of bevacizumab 7.5 mg/kg was
observed (Figure 2).
safety
The adverse event proﬁle, including overall incidence of adverse
events, severe (grade ‡3) adverse events and events of special
interest, has been previously reported [10]. Updated safety
results at the time of the follow-up OS analysis are consistent
with those previously reported and no new safety signals were
detected.
discussion
AVAiL is the second randomised phase III trial to show
a clinically signiﬁcant beneﬁt from bevacizumab-based therapy
in patients with advanced NSCLC. Efﬁcacy analyses showed
that the primary end point of prolonged PFS was met; the
response rate and response duration were also signiﬁcantly
improved [10]. However, the signiﬁcant prolongation of PFS
observed with bevacizumab did not translate into signiﬁcantly
longer OS. This is likely due to a number of confounding
factors. It is notable that all three treatment groups achieved
a median OS of >13 months, the longest reported to date in this
nonsquamous NSCLC patient population and well beyond the
historical survival benchmark of 1 year.
To establish the possible reasons for the extended OS seen
across all treatment groups and to ascertain why the signiﬁcant
OS beneﬁt of bevacizumab in E4599 was not conﬁrmed in
AVAiL, it is instructive to examine the impact of variables such
as baseline prognostic factors and postprotocol therapies.
Patients in the overall AVAiL population generally had slightly
more favourable prognostic features when compared with those
in the E4599 trial [9]: they were younger (median age 57–59
versus 63 years), 8% had dry stage IIIb (0% in E4599, which
only enrolled wet stage IIIb) and a high proportion had
adenocarcinoma histology (82%–85%) and were never smokers
(22%–26%) [10, 11]. Together, these factors are not only likely
to have contributed to the longest survival duration reported
for CG (13.1 months) in a predominantly non-Asian
population but may also explain the unusually high use of
second and subsequent lines of therapy. Indeed, it appears that
the long duration of survival in AVAiL may also reﬂect the
growing inﬂuence of further lines of therapy on patient
outcomes.
AVAiL was conducted at a time when several efﬁcacious
second-line therapies, such as the epidermal growth factor
receptor tyrosine kinase inhibitor erlotinib and pemetrexed,
becamewidelyusedinroutineclinicalpracticeandtheirusemay
have introduced a confounding factor in the OS end point
analysis. Our data show that the proportion of patients who
received poststudy therapies in AVAiL (62%) was one of the
highesteverreportedinNSCLCtrials(e.g.54%intheJMDBtrial
[12],57%intheFLEXtrial[13]).Additionally, thepercentageof
patients receiving second-line therapy was slightly higher for
placebo(65%)versuseitherbevacizumabgroup(61%);thismay
alsohaveledtoamorefavourablethanexpectedoutcomeforthe
placebo group. Although the various types of agents used in
the poststudy setting appeared to be balanced across study arms,
the real impact of these therapies is difﬁcult to assess, as speciﬁc
information on the combinations, dosing, compliance, duration
or sequencing of the therapies is not available. However, the
heterogeneityinpoststudytherapieswashigh(with>66different
regimens identiﬁed). The exploratory OS analysis for patients
who did not receive additional therapies indicates that when the
inﬂuence of second-line therapies is removed, bevacizumab may
have a favourable impact on OS over and above that of
chemotherapy alone. Clearly, the therapeutic options now
availableforthe treatmentofNSCLChave become morecomplex
andneedtobeindividuallytailoredtoachievethemostfavourable
patient outcomes. In a recent investigation [14], the effect of
bevacizumab on levels of circulating endothelial progenitor cells
differeddependingonwhether it wascombinedwithpaclitaxelor
Table 1. Poststudy therapy (ITT population)
Placebo + CG
(n = 347), n (%)
Bevacizumab 7.5 mg/kg +
CG (n = 345), n (%)
Bevacizumab 15 mg/kg +
CG (n = 351), n (%)
Patients with at least one treatment 224 (65) 210 (61) 214 (61)
Targeted therapy
Erlotinib 66 (19) 82 (24) 69 (20)
Geﬁtinib 20 (6) 18 (5) 15 (4)
Bevacizumab 2 (<1) 1 (<1) 2 (<1)
Chemotherapy
Taxane 93 (27) 76 (22) 84 (24)
Pemetrexed 52 (15) 47 (14) 46 (13)
Gemcitabine 20 (6) 18 (5) 21 (6)
Radiotherapy
a 66 (19) 76 (22) 60 (17)
CG, cisplatin–gemcitabine.
aIncluded palliative irradiation of bone metastases.
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different cytotoxic chemotherapy agents in a variable manner.
However, these ﬁndings were generated in preclinical tumour
models and have not been conﬁrmed in clinical trials.
As an increasing number of effective options for second-
and third-line therapies in advanced NSCLC become
available, the sensitivity of OS as a primary end point in
NSCLC trials is likely to be increasingly challenged. The OS
ﬁndings from the AVAiL and BETA Lung trials [15] are
consistent with this notion and tend to validate the adoption
of PFS as the primary end point in AVAiL. Both the Food and
Drug Administration [16] and the European Medicines
Agency [17] accept PFS as a valid measure of clinical beneﬁt,
particularly in situations where it is expected that further
lines of treatment may hamper the detection of a relevant OS
beneﬁt. Recent regulatory approval of a number of cancer
therapies on the basis of a PFS advantage underscores the
increasing importance and validity of PFS as an end point in
phase III clinical trials of oncologic agents where multiple
efﬁcacious lines of therapy are accepted clinical standards or
where there is unmet clinical need.
The safety proﬁle for bevacizumab plus CG in AVAiL was
previously reported [10] and no new safety signals were
observed in the current analysis, supporting the well-
established and manageable adverse event proﬁle for
bevacizumab.
In summary, the primary end point of AVAiL (PFS) was met
and the magnitude of bevacizumab beneﬁt was maintained
with longer follow-up. This magnitude (HR 0.75–0.85) is
clinically signiﬁcant, allowing patients to live longer without
their disease progressing. The ﬁnal analysis of the AVAiL data
conﬁrms the signiﬁcant prolongation of PFS when
bevacizumab is combined with CG, but the PFS ﬁnding did not
translate into a signiﬁcant OS beneﬁt. The positive results from
AVAiL, together with those from the E4599 study, demonstrate
that bevacizumab combined with standard platinum-based
chemotherapy doublets in the ﬁrst-line setting leads to
signiﬁcantly improved outcomes for patients with advanced
nonsquamous NSCLC.
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